Quince Therapeutics
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other neurological diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€276—415m (Dealroom.co estimates May 2018.)
Share price
$0.735 CRTX
South San Francisco California (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| EBITDA | (10.0m) | (12.0m) | (39.0m) | (79.0m) | (90.0m) | (50.0m) | (24.3m) |
| Profit | (12.0m) | (12.0m) | (37.0m) | (77.0m) | (90.0m) | (52.0m) | (31.4m) |
| EV / EBITDA | - | - | -36.1x | -8.7x | -3.0x | 1.3x | 0.7x |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | Grant | |
$1.0m | Seed | ||
$15.0m | Series A | ||
$7.6m | Debt | ||
$76.0m | Series B | ||
| N/A | N/A | IPO | |
* | N/A | $125m | Post IPO Equity |
| Total Funding | €83.6m | ||
